구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belinostat |
Overview Company | Acrotech Biopharma Inc. |
Overview Modality | CGT |
Overview Target | Adult T-cell Leukemia-Lymphoma |
Overview Indication | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral Therapy (ART) in the management of viral replication and infection, HIV latency |
MoA Mechanism | target only two of these pathway |
MoA Biomarker | Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma |
PK/PD Half-life | 1.1 h |
PK/PD Species | Mouse, Furthermore |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Furthermore |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Thrombocytopenia observed with vorinostat, panobinostat and romidepsin may stem from dual inhibi |
Toxicology CRS | Reported |
Clinical Safety signal | Thrombocytopenia observed with vorinostat, panobinostat and romidepsin may stem from dual inhibi |
Clinical Selected reported efficacy | ORR 25% |
Clinical Reported ORR | 25% |
Clinical Result source | ClinicalTrials.gov NCT00274651 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00274651 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Belinostat |
Overview Company | Acrotech Biopharma Inc. |
Overview Modality | CGT |
Overview Target | Adult T-cell Leukemia-Lymphoma |
Overview Indication | Breast Adenocarcinoma; Metastatic Breast Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral Therapy (ART) in the management of viral replication and infection, HIV latency |
MoA Mechanism | target only two of these pathway |
MoA Biomarker | Biomarker for Prognosis and Targeted Therapy in Diffuse Large B-cell Lymphoma |
PK/PD Half-life | 1.1 h |
PK/PD Species | Mouse, Furthermore |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Furthermore |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Thrombocytopenia observed with vorinostat, panobinostat and romidepsin may stem from dual inhibi |
Toxicology CRS | Reported |
Clinical Safety signal | Thrombocytopenia observed with vorinostat, panobinostat and romidepsin may stem from dual inhibi |
Clinical Selected reported efficacy | ORR 25% |
Clinical Reported ORR | 25% |
Clinical Result source | ClinicalTrials.gov NCT00274651 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT00274651 |
추천 비교
추천 비교